Skip to main content
Premium Trial:

Request an Annual Quote

MobiDiag Extends Distribution Agreement With PerkinElmer

NEW YORK (GenomeWeb) – Finnish MDx firm Mobidiag said today that it has expanded its distribution agreement with PerkinElmer subsidiary Wallac to include distribution of its Amplidiag product line in Israel and several countries in Africa.

Mobidiag's Amplidiag line includes in vitro diagnostic tests for the detection of gastrointestinal infections, including Clostridium difficile and bacterial gastroenteritis, and well as drug-resistant organisms, supported by cartridge-based multiplex PCR and microarray instruments.

Wallac has been distributing Amplidiag products in South Africa since January. Mobidiag CEO Tuomas Tenkanen said in a statement that the companies are now extending that deal to both speed up sales coverage in Africa — expanding to Botswana, Ghana, Ivory Coast, Kenya, Mauritius, Morocco, Mozambique, Nigeria, Rwanda, Senegal, and Uganda — and also to extend availability of the system into the Middle East.

"We are very pleased that PerkinElmer will continue to support us in our endeavor with its acknowledged expertise and worldwide leadership in the field of diagnostics," Tenakanen added.

Financial and other terms of the deal were not disclosed.

In Europe, Mobidiag has also steadily added distributors over the last year, covering Italy, Sweden and Norway, Portugal, and the UK, among others.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.